·Week of August 3-7, 2026

Clinical Trials Brief | August 10, 2026

This week: FDA licensing the first mRNA influenza vaccine six months after refusing to review it, FDA granting accelerated approval to RP1 after two rejections and over its own review team's recommendation, the European Commission formally revoking Tavneos over pivotal trial data handling, the MHRA reminding patients and prescribers that common medicines change how the body copes with heat, and Curium agreeing to buy Lantheus for up to $8 billion.

FDA licenses the first mRNA flu vaccine, six months after refusing to review it

What changed

On August 5, 2026, Moderna announced FDA approval of mFLUSIVA (mRNA-1010), a seasonal influenza vaccine, for adults aged 50 and older. It is the first mRNA-based influenza vaccine licensed in the US and Moderna's fourth approved product. The approval followed a unanimous vote by FDA's Vaccines and Related Biological Products Advisory Committee on June 18 that the vaccine's benefits outweigh its risks in adults 50 to 64 and 65 and older. The path was unusual. On February 10, CBER issued a refusal-to-file letter, questioning the Phase 3 trial's use of a standard-dose licensed flu vaccine as the comparator for adults 65 and older rather than a high-dose vaccine. About a week later, it reversed course and accepted an amended application. According to CIDRAP, Moderna then sought full approval for ages 50 to 64 and accelerated approval for 65 and older, with a postmarketing study in older adults. Goodwin reports that mRNA-1010 is also under review in the EU, Canada and Australia.

Why it matters

This is the first proof that mRNA can move beyond COVID-19 into a routine seasonal vaccine, and it will shape how regulators elsewhere approach the EU, Canadian and Australian filings. For trial design, the comparator dispute is the lasting lesson. According to reporting at the time, CBER had told Moderna in April 2024 that a standard-dose comparator would be acceptable, but the agency still challenged that choice at filing. The resolution, splitting the indication by age and attaching a postmarketing requirement for the older group, shows how comparator questions can now be settled through the label rather than through a new trial.

Takeaway

Vaccine sponsors should get comparator choices for older adults confirmed in writing at end-of-Phase 2, and revisit them if standard of care shifts during the trial, for example toward high-dose or adjuvanted vaccines. Expect the EU and other regulators to scrutinise the same question in their own reviews.

Sources

This item is grounded in Moderna's announcements of June 18 and August 5, 2026, and reporting by CIDRAP, Pharmacy Times/Patient Care and Goodwin.

FDA grants accelerated approval to RP1 after two rejections, overruling its own primary review team

What changed

On August 6, 2026, FDA granted accelerated approval to Tudriqev (vusolimogene oderparepvec, RP1, Replimune) in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease progressed on an anti-PD-1-based regimen. The approval is based on objective response rate and duration of response in the single-arm IGNYTE study, and continued approval depends on the ongoing confirmatory IGNYTE-3 trial. FDA's Summary Basis for Regulatory Action shows an original submission in November 2024, resubmissions in April and June 2026, and an action due date of August 2. It also records that the primary clinical review team did not recommend approval, while the Office of Therapeutic Products and the Oncology Center of Excellence recommended accelerated approval with a confirmatory postmarketing requirement. This followed the July 30 advisory committee vote of 10-3 that the IGNYTE results are evaluable and clinically meaningful, despite FDA's briefing document again questioning the response criteria and how much RP1 contributed to the effect on top of nivolumab.

Why it matters

This is a rare case where the internal disagreement is documented in the public record: reviewers said no, office leadership said yes, and the approval came on the same single-arm dataset that had already been rejected twice. Together with the deramiocel meeting a week earlier, it shows how much weight advisory committees now carry. It also shows that the substantial-evidence framework FDA set out in June still leaves wide discretion at the level of individual applications. For oncology sponsors, it confirms that durable responses in a refractory population can support accelerated approval of a combination, even when isolating each component's contribution is difficult.

Takeaway

Sponsors relying on single-arm combination data should expect FDA to probe the contribution of each component and the robustness of response assessment, and should design confirmatory trials that answer those questions directly. IGNYTE-3's conduct and timelines will now carry the regulatory weight for RP1.

Sources

This item is grounded in Replimune's SEC filings of August 6, 2026, FDA's Summary Basis for Regulatory Action, and coverage of the July 30 advisory committee.

The European Commission formally revokes Tavneos, closing the EU review triggered by pivotal-trial data handling

What changed

The European Commission revoked the EU marketing authorisation for Tavneos (avacopan) by an implementing decision dated August 4, 2026; the marketing authorisation holder, Vifor Fresenius Medical Care Renal Pharma, and CSL announced it on August 6. The decision adopts CHMP's June recommendation. CSL Vifor states that the revocation followed an Article 20 non-pharmacovigilance review, started because of concerns about data handling in the pivotal Phase 3 ADVOCATE trial before authorisation, and CHMP's conclusion that a positive benefit-risk balance could no longer be established. Tavneos will no longer be available for prescribing in the EU and EEA, and the company said it will work with EMA and national authorities to manage discontinuation.

Why it matters

This closes the EU chapter of a story this brief has followed since May. The legal basis matters: this was not a pharmacovigilance referral driven by new adverse reactions, but a review of whether the efficacy evidence could be trusted. In the US, Amgen has said it disagrees with FDA's April proposal to withdraw approval, and the UK review was still open at the time of the EU decision, so the product's status now differs between major markets. For inspectors and sponsors, the precedent is that data-handling problems found years after approval can remove a product entirely, not just add a warning.

Takeaway

The practical lesson for trial teams is traceability. Every analysis dataset supporting a pivotal claim should be reproducible from source, with an audit trail that would survive scrutiny years later. Clinicians in the EU should complete transitions for remaining patients, keeping in mind the post-discontinuation liver monitoring covered in the July 20 issue.

Sources

This item is grounded in the CSL Vifor announcement of August 6, 2026 and EMA's Tavneos product page.

MHRA warns that common medicines change how the body copes with heat, a growing issue for home-based trial supply

What changed

On August 7, 2026, as part of its "Summer-proof your health" campaign, the UK MHRA issued advice on medicines that increase sensitivity to sunlight or the risk of dehydration. It reminded patients that diuretics increase fluid loss and that some treatments make skin burn faster or more severely. It told people to check the patient information leaflet for advice on sun exposure and hydration, and not to stop prescribed medicines during hot weather without advice. Earlier MHRA heatwave advice, issued in late May, highlighted methotrexate as a cause of severe photosensitivity even at low doses, and noted that insulin and metformin can increase dehydration risk or make early symptoms harder to recognise. It also advised storing medicines somewhere cool and dry, out of direct sunlight.

Why it matters

This is a public-health reminder rather than a new signal, but it lands on a real operational gap in clinical research. Direct-to-participant shipping and home storage of investigational products, which ICH E6(R3) Annex 2 now addresses explicitly, move temperature control out of the pharmacy and into participants' homes and cars. The NHS Specialist Pharmacy Service also flags that heat and sunlight may affect the stability of adrenaline auto-injectors. Heat-related adverse events, such as dehydration on diuretics or SGLT2 inhibitors, or acute kidney injury with NSAIDs, can also be misattributed to the study drug during heatwaves.

Takeaway

For decentralised and hybrid trials, summer is the time to check IMP storage instructions for participants, temperature-excursion reporting routes and logger use for home shipments. Safety reviewers should consider ambient temperature as a confounder when assessing clusters of dehydration-related events.

Curium agrees to buy Lantheus for up to $8 billion, consolidating the radiopharmaceutical supply behind PSMA and amyloid PET

What changed

On August 3, 2026, Curium and Lantheus announced a definitive agreement under which Curium US will acquire Lantheus for $102.50 per share in cash at closing, plus contingent value rights worth up to $12.00 per share tied to commercial milestones through 2030. That is a total of up to $114.50 per share and a transaction value of up to about $8.0 billion. According to Pulse 2.0, the maximum consideration represents a 38% premium to Lantheus's unaffected 60-day volume-weighted average price. The Lantheus board approved the deal unanimously, and Lantheus will be delisted after closing because Curium is privately held. Lantheus's portfolio includes Pylarify (piflufolastat F 18 PSMA PET), the Definity ultrasound contrast agent and Neuraceq (florbetaben amyloid PET). The CVR milestones include up to $8 per share for prostate cancer diagnostics and up to $3 per share for neurology diagnostics.

Why it matters

Radiopharmaceuticals are a supply-chain-sensitive part of clinical research. Many oncology, neurology and cardiology trials depend on PET tracers that have short half-lives and must be produced in regional networks and delivered on the day of the scan. Combining two of the largest suppliers under private ownership may improve manufacturing scale, but it also concentrates supply. The CVR structure shows where the buyer expects growth: PSMA and neurology diagnostics, including amyloid imaging, which is linked to anti-amyloid therapies.

Takeaway

Sponsors running imaging-dependent trials with Pylarify, Neuraceq or Curium tracers should confirm supply agreements, manufacturing-site continuity and imaging-charter assumptions before closing, and include tracer supply in study risk registers. Imaging core labs should expect sponsor and vendor contracts to be reassigned.

Clinical Trials Brief is an educational commentary archive, not a real-time news service. Confirmed facts are based on publicly cited sources where possible. Analytical comments, comparisons, and forward-looking views are personal interpretation unless otherwise stated.